Optimized Expression of Full-Length IgG1 Antibody in a Common E. coli Strain

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Chan, Conrad En Zuo ^a,b   Lim, Angeline Pei Chiew ^a   Chan, Annie Hoi Yi ^a   MacAry, Paul A ^b   Hanson, Brendon John ^a  

^a DSO NATIONAL LABORATORIES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; ANTIBODY;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESCHERICHIA COLI; MAMMAL CELL; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TRANSLATION REGULATION; ANTIBODY AFFINITY; BIOSYNTHESIS; GENETICS; KINETICS; METHODOLOGY; MOLECULAR CLONING; TECHNIQUE;

MAMMALIA; PROKARYOTA;

ANTIBODIES; ANTIBODY AFFINITY; CLONING, MOLECULAR; ESCHERICHIA COLI; IMMUNOGLOBULIN G; KINETICS; METHODS;

EID: 77956311231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010261     Document Type: Article

References (16)

1. Chadd HE, Chamow SM (2001) Therapeutic antibody expression technology. Curr Opin Biotechnol 12: 188-194.
2. Jefferis R, Lund J, Pound JD (1998) IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163: 59-76.
3. Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143: 2595-2601.
4. Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58: 640-656.
5. Jefferis R (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21: 11-16.
6. Wright A, Morrison SL (1994) Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 180: 1087-1096.
7. Wright A, Morrison SL (1998) Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160: 3393-3402.
8. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, et al. (2002) Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 263: 133- 147.
9. Mazor Y, Van Blarcom T, Mabry R, Iverson BL, Georgiou G (2007) Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 25: 563-565.
10. Venturi M, Seifert C, Hunte C (2002) High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J Mol Biol 315: 1-8.
11. Levy R, Weiss R, Chen G, Iverson BL, Georgiou G (2001) Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif 23: 338-347.
12. Simmons LC, Yansura DG (1996) Translational level is a critical factor for the secretion of heterologous proteins in Escherichia coli. Nat Biotechnol 14: 629-634.
13. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, et al. (2005) Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33: e21.
14. Lutz R, Bujard H (1997) Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. Nucleic Acids Res 25: 1203-1210.
15. Skerra A (1994) Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 151: 131-135.
16. Walker MR, Lund J, Thompson KM, Jefferis R (1989) Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259: 347-353.